Skip to Content

Cell-Free Proteins

Bacterial innards plus chemical soup yields ingredients for drugs.

Protein-based drugs are a fast-growing class of new medicines, but they cost 20 to 100 times more to make than conventional drugs. One reason is that proteins can only be made by living cells, which are not very efficient producers. Researchers at Stanford University believe they can cut costs by doing away with the cells and instead exploiting the protein-making machinery inside them. Chemical engineer Jim Swartz and his colleagues have come up with a way of growing bacteria, busting them open, pulling out their innards, and adding a soup of chemicals that mimics the inside of a cell. Also tossed into the mix are amino acids (proteins’ building blocks), enzymes, and strands of DNA that encode the protein to be churned out. With no cells to keep alive, all those parameters can be fine-tuned for protein production. Swartz says the method can boost protein production five- to 10-fold and cut up to 80 percent of the capital costs. The researchers founded  Fundamental Applied Biology in San Francisco, CA, to commercialize the technique.

Other Prototypes:
Videoconferencing by the Numbers

Keep Reading

Most Popular

This startup wants to copy you into an embryo for organ harvesting

With plans to create realistic synthetic embryos, grown in jars, Renewal Bio is on a journey to the horizon of science and ethics.

VR is as good as psychedelics at helping people reach transcendence

On key metrics, a VR experience elicited a response indistinguishable from subjects who took medium doses of LSD or magic mushrooms.

This nanoparticle could be the key to a universal covid vaccine

Ending the covid pandemic might well require a vaccine that protects against any new strains. Researchers may have found a strategy that will work.

Stay connected

Illustration by Rose Wong

Get the latest updates from
MIT Technology Review

Discover special offers, top stories, upcoming events, and more.

Thank you for submitting your email!

Explore more newsletters

It looks like something went wrong.

We’re having trouble saving your preferences. Try refreshing this page and updating them one more time. If you continue to get this message, reach out to us at customer-service@technologyreview.com with a list of newsletters you’d like to receive.